Jump Financial LLC Purchases 37,935 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Jump Financial LLC grew its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 318.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 49,865 shares of the company's stock after acquiring an additional 37,935 shares during the quarter. Jump Financial LLC owned 0.10% of PROCEPT BioRobotics worth $4,015,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PRCT. Raleigh Capital Management Inc. bought a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $32,000. Signaturefd LLC raised its position in shares of PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after buying an additional 145 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $58,000. Wilmington Savings Fund Society FSB acquired a new stake in PROCEPT BioRobotics during the third quarter worth approximately $64,000. Finally, Arcadia Investment Management Corp MI bought a new position in PROCEPT BioRobotics during the 4th quarter worth $64,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PRCT. Truist Financial cut their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Morgan Stanley cut their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of "Moderate Buy" and an average target price of $91.43.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $52.81 on Thursday. The stock has a market cap of $2.89 billion, a PE ratio of -27.08 and a beta of 1.09. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 12-month low of $47.04 and a 12-month high of $103.81. The business's 50-day moving average price is $60.08 and its two-hundred day moving average price is $75.17.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. As a group, analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,455 shares of company stock worth $368,322. Insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.